LAMEYNARDIE CMC Consulting

About LAMEYNARDIE CMC Consulting

Lameynardie CMC Consulting helps biotech and cell & gene therapy companies navigate the complex path from development to clinical and commercial readiness. Founded by Stephane Lameynardie, PharmD — a pharmaceutical operations leader with over 24 years of experience in CMC development, supply chain, and quality systems — the consultancy brings deep expertise in: Raw material governance: supplier qualification, specification setting, GMP compliance, and integration into IND/IMPD filings. Cell & Gene Therapy programs: viral vectors, plasmids, iPSCs, and both autologous and allogeneic therapies. CMC strategy & execution: regulatory filings, CDMO partnerships, technology transfers, and quality frameworks. Clinical supply chains: ensuring robust, compliant, and patient-focused delivery across geographies. Stephane has held leadership roles at Novartis, Ferring, Enara Bio, Advesya, and Tenpoint Therapeutics, where he built CMC strategies and operations across hematology, ophthalmology, and immunology programs. At Lameynardie CMC Consulting, we partner with biotech teams to: Establish effective CMC governance frameworks Build and manage strategic CDMO relationships Ensure regulatory alignment and GMP readiness Accelerate development timelines while safeguarding quality and patient safety Our mission is to give innovators the CMC confidence and operational clarity needed to bring transformative therapies to patients faster.

View contact profiles from LAMEYNARDIE CMC Consulting